Early phase limited sampling strategy characterizing tacrolimus and mycophenolic acid pharmacokinetics adapted to the maintenance phase of renal transplant patients

Therapeutic Drug Monitoring

Volumn 31, Issue 4, 2009, Pages 467-474

  Miura, Masatomo ^a   Satoh, Shigeru ^b   Niioka, Takenori ^c   Kagaya, Hideaki ^a   Saito, Mitsuru ^b   Hayakari, Makoto ^c   Habuchi, Tomonori ^b   Suzuki, Toshio ^a  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

AUC; Limited sampling strategy; Mycophenolic acid; Renal transplantation, therapeutic drug monitoring; Tacrolimus

Indexed keywords

MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; ENTEROHEPATIC CIRCULATION; EVENING DOSAGE; FEMALE; GRAFT RECIPIENT; HUMAN; JAPANESE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; SAMPLING; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AREA UNDER CURVE; BODY WEIGHT; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MYCOPHENOLIC ACID; REGRESSION ANALYSIS; TACROLIMUS; YOUNG ADULT;

EID: 68449098790     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181ae44b9     Document Type: Article

References (34)

1. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs. 2003;63:1247-1297.
2. Roth D, Colona J, Burke GW, et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. Transplantation. 1998;65:248-252.
3. Squifflet JP, Backman L, Claesson K, et al. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients. Transplantation. 2001;72:63-69.
4. Jusko WJ, Thomson AW, Fung J, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995;17:606-614.
5. Shaw LM, Kaplan B, DeNofrio D, et al. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit. 2000;22:14-19.
6. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 2000;22:20-26.
7. Hale MD, Nicholls AJ, Bullingham RES, et al. The pharmacokinetic- pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther. 1998;64:672-683.
8. Shaw LM, Korecka M, DeNofrio D, et al. Pharmacokinetic, pharmaco-dynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal transplant patients. Clin Biochem. 2001;34:17-22.
9. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993;54:205-218.
10. Primmet DRN, Levine M, Kovarik JM, et al. Cyclosporine monitoring in patients with renal transplants: two-or-three-points methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit. 1998;20:276-283.
11. Miura M, Satoh S, Niioka T, et al. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit. 2008;30:52-59.
12. Kagaya H, Inoue K, Miura M, et al. Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. Yakugaku Zasshi. 2006;126:1357-1362.
13. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
14. Krouwer JS, Monti KL. A simple, graphical method to evaluate laboratory assays. Eur J Clin Chem Clin Biochem. 1995;33:525-527.
15. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit. 2001;23:100-114.
16. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit. 2003;25:137-157.
17. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
18. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001;23:305-315.
19. Bernard O, Guillemette C. The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants. Drug Metab Dispos. 2004;32:775-778.
20. Picard N, Ratanasavanh D, Prémaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005;33:139-146.
21. Ting LS, Villeneuve E, Ensom MH. Beyond cyclosporine: a systematic review of limited sampling strategies for other immunosuppressants. Ther Drug Monit. 2006;28:419-430.
22. Yeung S, Tong KL, Tsang WK, et al. Determination of mycophenolate area under the curve by limited sampling strategy. Transplant Proc. 2001;33:1052-1053.
23. Pawinski T, Hale M, Korecka M, et al. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem. 2002;48:1497-1504.
24. Le Guellec C, Buchler M, Giraudeau B, et al. Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy. Eur J Clin Pharmacol. 2002;57:805-811.
25. van Hest RM, Mathot RA, Vulto AG, et al. Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit. 2004;26:620-625.
26. Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999;66:492-500.
27. Cho EK, Han DJ, Kim SC, et al. Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. J Clin Pharmacol. 2004;44:743-750.
28. Zicheng Y, Peijun Z, Da X, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. Br J Clin Pharmacol. 2006;62:446-452.
29. Zhou PJ, Xu D, Yu ZC, et al. Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. Clin Pharmacokinet. 2007;46:389-401.
30. van Gelder T, Hilbrands LB, Vanrenterghem Y, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation. 1999;68:261-266.
31. Kiberd BA, Lawen J, Fraser AD, et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant. 2004;4:1079-1083.
32. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043-1051.
33. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant. 2007;7:2496-2503.
34. Prémaud A, Debord J, Rousseau A, et al. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet. 2005;44:837-847.